The large patient cohorts in our hospitals provided an opportunity for us to study TP53 mutation in early-stage MM patients, which brings insight into the clinical significance of TP53 in newly diagnosed MM patients and also disease progression. The gene discussed is TP53; the disease is Miyoshi myopathy.